The transferrin receptor and the targeted delivery of therapeutic agents against cancer
- Autores
- Daniels, Tracy R.; Bernabeu, Ezequiel Adrian; Rodríguez, José A.; Patel, Shabnum; Kozman, Maggie; Chiappetta, Diego Andrés; Holler, Eggehard; Ljubimova, Julia Y.; Helguera, Gustavo Fernando; Penichet, Manuel L.
- Año de publicación
- 2012
- Idioma
- inglés
- Tipo de recurso
- artículo
- Estado
- versión publicada
- Descripción
- Background: Traditional cancer therapy can be successful in destroying tumors, but can also cause dangerous side effects. Therefore, many targeted therapies are in development. The transferrin receptor (TfR) functions in cellular iron uptake through its interaction with transferrin. This receptor is an attractive molecule for the targeted therapy of cancer since it is upregulated on the surface of many cancer types and is efficiently internalized. This receptor can be targeted in two ways: 1) for the delivery of therapeutic molecules into malignant cells or 2) to block the natural function of the receptor leading directly to cancer cell death. Scope of revie: In the present article we discuss the strategies used to target the TfR for the delivery of therapeutic agents into cancer cells. We provide a summary of the vast types of anti-cancer drugs that have been delivered into cancer cells employing a variety of receptor binding molecules including Tf, anti-TfR antibodies, or TfR-binding peptides alone or in combination with carrier molecules including nanoparticles and viruses. Major conclusions: Targeting the TfR has been shown to be effective in delivering many different therapeutic agents and causing cytotoxic effects in cancer cells in vitro and in vivo. General significance: The extensive use of TfR for targeted therapy attests to the versatility of targeting this receptor for therapeutic purposes against malignant cells. More advances in this area are expected to further improve the therapeutic potential of targeting the TfR for cancer therapy leading to an increase in the number of clinical trials of molecules targeting this receptor. This article is part of a Special Issue entitled Transferrins: molecular mechanisms of iron transport and disorders.
Fil: Daniels, Tracy R.. University of California at Los Angeles; Estados Unidos
Fil: Bernabeu, Ezequiel Adrian. Consejo Nacional de Investigaciones Científicas y Técnicas; Argentina. Universidad de Buenos Aires. Facultad de Farmacia y Bioquímica. Departamento de Tecnología Farmacéutica; Argentina
Fil: Rodríguez, José A.. University of California at Los Angeles; Estados Unidos
Fil: Patel, Shabnum. University of California at Los Angeles; Estados Unidos
Fil: Kozman, Maggie. University of California at Los Angeles; Estados Unidos
Fil: Chiappetta, Diego Andrés. Consejo Nacional de Investigaciones Científicas y Técnicas; Argentina. Universidad de Buenos Aires. Facultad de Farmacia y Bioquímica. Departamento de Tecnología Farmacéutica; Argentina
Fil: Holler, Eggehard. Cedars Sinai Medical Center; Estados Unidos
Fil: Ljubimova, Julia Y.. Cedars Sinai Medical Center; Estados Unidos
Fil: Helguera, Gustavo Fernando. Consejo Nacional de Investigaciones Científicas y Técnicas; Argentina. Universidad de Buenos Aires. Facultad de Farmacia y Bioquímica. Departamento de Tecnología Farmacéutica; Argentina
Fil: Penichet, Manuel L.. University of California at Los Angeles; Estados Unidos - Materia
-
Transferrin Receptor
Cancer
Nanoparticle
Immnunotoxin
Delivery
Conjugate - Nivel de accesibilidad
- acceso abierto
- Condiciones de uso
- https://creativecommons.org/licenses/by-nc-nd/2.5/ar/
- Repositorio
- Institución
- Consejo Nacional de Investigaciones Científicas y Técnicas
- OAI Identificador
- oai:ri.conicet.gov.ar:11336/14137
Ver los metadatos del registro completo
id |
CONICETDig_5ed5d1bc5ff227f0fe0ca72afca156a7 |
---|---|
oai_identifier_str |
oai:ri.conicet.gov.ar:11336/14137 |
network_acronym_str |
CONICETDig |
repository_id_str |
3498 |
network_name_str |
CONICET Digital (CONICET) |
spelling |
The transferrin receptor and the targeted delivery of therapeutic agents against cancerDaniels, Tracy R.Bernabeu, Ezequiel AdrianRodríguez, José A.Patel, ShabnumKozman, MaggieChiappetta, Diego AndrésHoller, EggehardLjubimova, Julia Y.Helguera, Gustavo FernandoPenichet, Manuel L.Transferrin ReceptorCancerNanoparticleImmnunotoxinDeliveryConjugatehttps://purl.org/becyt/ford/2.10https://purl.org/becyt/ford/2Background: Traditional cancer therapy can be successful in destroying tumors, but can also cause dangerous side effects. Therefore, many targeted therapies are in development. The transferrin receptor (TfR) functions in cellular iron uptake through its interaction with transferrin. This receptor is an attractive molecule for the targeted therapy of cancer since it is upregulated on the surface of many cancer types and is efficiently internalized. This receptor can be targeted in two ways: 1) for the delivery of therapeutic molecules into malignant cells or 2) to block the natural function of the receptor leading directly to cancer cell death. Scope of revie: In the present article we discuss the strategies used to target the TfR for the delivery of therapeutic agents into cancer cells. We provide a summary of the vast types of anti-cancer drugs that have been delivered into cancer cells employing a variety of receptor binding molecules including Tf, anti-TfR antibodies, or TfR-binding peptides alone or in combination with carrier molecules including nanoparticles and viruses. Major conclusions: Targeting the TfR has been shown to be effective in delivering many different therapeutic agents and causing cytotoxic effects in cancer cells in vitro and in vivo. General significance: The extensive use of TfR for targeted therapy attests to the versatility of targeting this receptor for therapeutic purposes against malignant cells. More advances in this area are expected to further improve the therapeutic potential of targeting the TfR for cancer therapy leading to an increase in the number of clinical trials of molecules targeting this receptor. This article is part of a Special Issue entitled Transferrins: molecular mechanisms of iron transport and disorders.Fil: Daniels, Tracy R.. University of California at Los Angeles; Estados UnidosFil: Bernabeu, Ezequiel Adrian. Consejo Nacional de Investigaciones Científicas y Técnicas; Argentina. Universidad de Buenos Aires. Facultad de Farmacia y Bioquímica. Departamento de Tecnología Farmacéutica; ArgentinaFil: Rodríguez, José A.. University of California at Los Angeles; Estados UnidosFil: Patel, Shabnum. University of California at Los Angeles; Estados UnidosFil: Kozman, Maggie. University of California at Los Angeles; Estados UnidosFil: Chiappetta, Diego Andrés. Consejo Nacional de Investigaciones Científicas y Técnicas; Argentina. Universidad de Buenos Aires. Facultad de Farmacia y Bioquímica. Departamento de Tecnología Farmacéutica; ArgentinaFil: Holler, Eggehard. Cedars Sinai Medical Center; Estados UnidosFil: Ljubimova, Julia Y.. Cedars Sinai Medical Center; Estados UnidosFil: Helguera, Gustavo Fernando. Consejo Nacional de Investigaciones Científicas y Técnicas; Argentina. Universidad de Buenos Aires. Facultad de Farmacia y Bioquímica. Departamento de Tecnología Farmacéutica; ArgentinaFil: Penichet, Manuel L.. University of California at Los Angeles; Estados UnidosElsevier Science2012-03info:eu-repo/semantics/articleinfo:eu-repo/semantics/publishedVersionhttp://purl.org/coar/resource_type/c_6501info:ar-repo/semantics/articuloapplication/pdfapplication/pdfapplication/pdfhttp://hdl.handle.net/11336/14137Daniels, Tracy R.; Bernabeu, Ezequiel Adrian; Rodríguez, José A.; Patel, Shabnum; Kozman, Maggie; et al.; The transferrin receptor and the targeted delivery of therapeutic agents against cancer; Elsevier Science; Biochimica Et Biophysica Acta- General Subjects; 1820; 3; 3-2012; 291-3170304-4165enginfo:eu-repo/semantics/altIdentifier/url/http://www.sciencedirect.com/science/article/pii/S0304416511001826info:eu-repo/semantics/altIdentifier/doi/10.1016/j.bbagen.2011.07.016info:eu-repo/semantics/altIdentifier/url/https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3500658/info:eu-repo/semantics/openAccesshttps://creativecommons.org/licenses/by-nc-nd/2.5/ar/reponame:CONICET Digital (CONICET)instname:Consejo Nacional de Investigaciones Científicas y Técnicas2025-09-29T10:36:38Zoai:ri.conicet.gov.ar:11336/14137instacron:CONICETInstitucionalhttp://ri.conicet.gov.ar/Organismo científico-tecnológicoNo correspondehttp://ri.conicet.gov.ar/oai/requestdasensio@conicet.gov.ar; lcarlino@conicet.gov.arArgentinaNo correspondeNo correspondeNo correspondeopendoar:34982025-09-29 10:36:38.702CONICET Digital (CONICET) - Consejo Nacional de Investigaciones Científicas y Técnicasfalse |
dc.title.none.fl_str_mv |
The transferrin receptor and the targeted delivery of therapeutic agents against cancer |
title |
The transferrin receptor and the targeted delivery of therapeutic agents against cancer |
spellingShingle |
The transferrin receptor and the targeted delivery of therapeutic agents against cancer Daniels, Tracy R. Transferrin Receptor Cancer Nanoparticle Immnunotoxin Delivery Conjugate |
title_short |
The transferrin receptor and the targeted delivery of therapeutic agents against cancer |
title_full |
The transferrin receptor and the targeted delivery of therapeutic agents against cancer |
title_fullStr |
The transferrin receptor and the targeted delivery of therapeutic agents against cancer |
title_full_unstemmed |
The transferrin receptor and the targeted delivery of therapeutic agents against cancer |
title_sort |
The transferrin receptor and the targeted delivery of therapeutic agents against cancer |
dc.creator.none.fl_str_mv |
Daniels, Tracy R. Bernabeu, Ezequiel Adrian Rodríguez, José A. Patel, Shabnum Kozman, Maggie Chiappetta, Diego Andrés Holler, Eggehard Ljubimova, Julia Y. Helguera, Gustavo Fernando Penichet, Manuel L. |
author |
Daniels, Tracy R. |
author_facet |
Daniels, Tracy R. Bernabeu, Ezequiel Adrian Rodríguez, José A. Patel, Shabnum Kozman, Maggie Chiappetta, Diego Andrés Holler, Eggehard Ljubimova, Julia Y. Helguera, Gustavo Fernando Penichet, Manuel L. |
author_role |
author |
author2 |
Bernabeu, Ezequiel Adrian Rodríguez, José A. Patel, Shabnum Kozman, Maggie Chiappetta, Diego Andrés Holler, Eggehard Ljubimova, Julia Y. Helguera, Gustavo Fernando Penichet, Manuel L. |
author2_role |
author author author author author author author author author |
dc.subject.none.fl_str_mv |
Transferrin Receptor Cancer Nanoparticle Immnunotoxin Delivery Conjugate |
topic |
Transferrin Receptor Cancer Nanoparticle Immnunotoxin Delivery Conjugate |
purl_subject.fl_str_mv |
https://purl.org/becyt/ford/2.10 https://purl.org/becyt/ford/2 |
dc.description.none.fl_txt_mv |
Background: Traditional cancer therapy can be successful in destroying tumors, but can also cause dangerous side effects. Therefore, many targeted therapies are in development. The transferrin receptor (TfR) functions in cellular iron uptake through its interaction with transferrin. This receptor is an attractive molecule for the targeted therapy of cancer since it is upregulated on the surface of many cancer types and is efficiently internalized. This receptor can be targeted in two ways: 1) for the delivery of therapeutic molecules into malignant cells or 2) to block the natural function of the receptor leading directly to cancer cell death. Scope of revie: In the present article we discuss the strategies used to target the TfR for the delivery of therapeutic agents into cancer cells. We provide a summary of the vast types of anti-cancer drugs that have been delivered into cancer cells employing a variety of receptor binding molecules including Tf, anti-TfR antibodies, or TfR-binding peptides alone or in combination with carrier molecules including nanoparticles and viruses. Major conclusions: Targeting the TfR has been shown to be effective in delivering many different therapeutic agents and causing cytotoxic effects in cancer cells in vitro and in vivo. General significance: The extensive use of TfR for targeted therapy attests to the versatility of targeting this receptor for therapeutic purposes against malignant cells. More advances in this area are expected to further improve the therapeutic potential of targeting the TfR for cancer therapy leading to an increase in the number of clinical trials of molecules targeting this receptor. This article is part of a Special Issue entitled Transferrins: molecular mechanisms of iron transport and disorders. Fil: Daniels, Tracy R.. University of California at Los Angeles; Estados Unidos Fil: Bernabeu, Ezequiel Adrian. Consejo Nacional de Investigaciones Científicas y Técnicas; Argentina. Universidad de Buenos Aires. Facultad de Farmacia y Bioquímica. Departamento de Tecnología Farmacéutica; Argentina Fil: Rodríguez, José A.. University of California at Los Angeles; Estados Unidos Fil: Patel, Shabnum. University of California at Los Angeles; Estados Unidos Fil: Kozman, Maggie. University of California at Los Angeles; Estados Unidos Fil: Chiappetta, Diego Andrés. Consejo Nacional de Investigaciones Científicas y Técnicas; Argentina. Universidad de Buenos Aires. Facultad de Farmacia y Bioquímica. Departamento de Tecnología Farmacéutica; Argentina Fil: Holler, Eggehard. Cedars Sinai Medical Center; Estados Unidos Fil: Ljubimova, Julia Y.. Cedars Sinai Medical Center; Estados Unidos Fil: Helguera, Gustavo Fernando. Consejo Nacional de Investigaciones Científicas y Técnicas; Argentina. Universidad de Buenos Aires. Facultad de Farmacia y Bioquímica. Departamento de Tecnología Farmacéutica; Argentina Fil: Penichet, Manuel L.. University of California at Los Angeles; Estados Unidos |
description |
Background: Traditional cancer therapy can be successful in destroying tumors, but can also cause dangerous side effects. Therefore, many targeted therapies are in development. The transferrin receptor (TfR) functions in cellular iron uptake through its interaction with transferrin. This receptor is an attractive molecule for the targeted therapy of cancer since it is upregulated on the surface of many cancer types and is efficiently internalized. This receptor can be targeted in two ways: 1) for the delivery of therapeutic molecules into malignant cells or 2) to block the natural function of the receptor leading directly to cancer cell death. Scope of revie: In the present article we discuss the strategies used to target the TfR for the delivery of therapeutic agents into cancer cells. We provide a summary of the vast types of anti-cancer drugs that have been delivered into cancer cells employing a variety of receptor binding molecules including Tf, anti-TfR antibodies, or TfR-binding peptides alone or in combination with carrier molecules including nanoparticles and viruses. Major conclusions: Targeting the TfR has been shown to be effective in delivering many different therapeutic agents and causing cytotoxic effects in cancer cells in vitro and in vivo. General significance: The extensive use of TfR for targeted therapy attests to the versatility of targeting this receptor for therapeutic purposes against malignant cells. More advances in this area are expected to further improve the therapeutic potential of targeting the TfR for cancer therapy leading to an increase in the number of clinical trials of molecules targeting this receptor. This article is part of a Special Issue entitled Transferrins: molecular mechanisms of iron transport and disorders. |
publishDate |
2012 |
dc.date.none.fl_str_mv |
2012-03 |
dc.type.none.fl_str_mv |
info:eu-repo/semantics/article info:eu-repo/semantics/publishedVersion http://purl.org/coar/resource_type/c_6501 info:ar-repo/semantics/articulo |
format |
article |
status_str |
publishedVersion |
dc.identifier.none.fl_str_mv |
http://hdl.handle.net/11336/14137 Daniels, Tracy R.; Bernabeu, Ezequiel Adrian; Rodríguez, José A.; Patel, Shabnum; Kozman, Maggie; et al.; The transferrin receptor and the targeted delivery of therapeutic agents against cancer; Elsevier Science; Biochimica Et Biophysica Acta- General Subjects; 1820; 3; 3-2012; 291-317 0304-4165 |
url |
http://hdl.handle.net/11336/14137 |
identifier_str_mv |
Daniels, Tracy R.; Bernabeu, Ezequiel Adrian; Rodríguez, José A.; Patel, Shabnum; Kozman, Maggie; et al.; The transferrin receptor and the targeted delivery of therapeutic agents against cancer; Elsevier Science; Biochimica Et Biophysica Acta- General Subjects; 1820; 3; 3-2012; 291-317 0304-4165 |
dc.language.none.fl_str_mv |
eng |
language |
eng |
dc.relation.none.fl_str_mv |
info:eu-repo/semantics/altIdentifier/url/http://www.sciencedirect.com/science/article/pii/S0304416511001826 info:eu-repo/semantics/altIdentifier/doi/10.1016/j.bbagen.2011.07.016 info:eu-repo/semantics/altIdentifier/url/https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3500658/ |
dc.rights.none.fl_str_mv |
info:eu-repo/semantics/openAccess https://creativecommons.org/licenses/by-nc-nd/2.5/ar/ |
eu_rights_str_mv |
openAccess |
rights_invalid_str_mv |
https://creativecommons.org/licenses/by-nc-nd/2.5/ar/ |
dc.format.none.fl_str_mv |
application/pdf application/pdf application/pdf |
dc.publisher.none.fl_str_mv |
Elsevier Science |
publisher.none.fl_str_mv |
Elsevier Science |
dc.source.none.fl_str_mv |
reponame:CONICET Digital (CONICET) instname:Consejo Nacional de Investigaciones Científicas y Técnicas |
reponame_str |
CONICET Digital (CONICET) |
collection |
CONICET Digital (CONICET) |
instname_str |
Consejo Nacional de Investigaciones Científicas y Técnicas |
repository.name.fl_str_mv |
CONICET Digital (CONICET) - Consejo Nacional de Investigaciones Científicas y Técnicas |
repository.mail.fl_str_mv |
dasensio@conicet.gov.ar; lcarlino@conicet.gov.ar |
_version_ |
1844614387404374016 |
score |
13.070432 |